-+ 0.00%
-+ 0.00%
-+ 0.00%

Korro Bio Presents Oral, Poster Presentations Of Data From Its Oligonucleotide Delivery Based RNA Editing Technology

Benzinga·04/16/2026 11:34:27
Listen to the news

Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) will take place at the following scientific conferences:

3rd International Conference on Ureagenesis Defects and Allied Conditions, April 22-24 in Pozzuoli, Italy

Oral presentation title: KRRO-121, a GalNAc-conjugated oligonucleotide stabilizing Glutamine Synthetase, demonstrates robust ammonia clearance in preclinical hyperammonemia models
Speaker: Maria Dafne Cardamone, Ph.D, Associate Director, Biology, Korro Bio, Inc.